Europe Epigenetics Market

The Europe epigenetics market is anticipated to reach USD 1.22 billion by 2030 from USD 0.63 billion in 2025, at a CAGR of 14.1% during the forecast period. Major factors supporting growth in the Europe epigenetics market include vigorous academic and biopharma R&D activity, supported by large research programs in oncology and precision medicine.

The Europe epigenetics market is competitive. Prominent players in the Europe epigenetics market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), QIAGEN (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Fios Genomics (UK), among others.

To know about the assumptions considered for the study download the pdf brochure

In April 2025, QIAGEN launched the QIAseq Multimodal Cancer Genomics Panel, designed to advance cancer genomic profiling by enabling comprehensive analysis of key biomarkers across both DNA and RNA. This panel supports applications such as targeted oncology research, biomarker discovery, and translational medicine. 
             
Thermo Fisher Scientific Inc. leads the Europe epigenetics market with a wide product range that includes sample preparation, nucleic acid workflows, qPCR, and sequencing, boosting demand for consumables for methylation and chromatin studies. The company has a strong presence across European academic institutes, biopharma R&D sites, and CROs through a well-established distribution and service network. Thermo’s integrated sample-to-data workflows help customers reduce variability and improve turnaround times. This strengthens demand for consumables across large-cohort epigenomics projects. 

Illumina, Inc. holds a strong position in Europe epigenetics market through its extensive sequencing offerings and widespread use in high-throughput epigenome profiling programs. Its platforms are commonly used for methylation sequencing and large-scale research initiatives where throughput and standardization are important. Illumina benefits from penetration in national genomics centers, academic institutes, and pharma-led translational studies. Strong compatibility with downstream informatics also supports scalable analysis across multi-site European projects.

Merck KGaA is a major player in the Europe epigenetics market, supported by its product offerings, including antibodies, chromatin biology reagents, and epigenetics assay kits, which are used across ChIP and related workflows. Merck is well-positioned in terms of quality, documentation, and supply reliability for research and regulated laboratory environments. Their portfolio ensures consistent performance, driving steady demand across universities, research institutes, and biopharmaceutical discovery labs in Europe.

Market Ranking

The Europe epigenetics market is moderately consolidated, with leading suppliers strengthening their share by providing comprehensive workflow coverage, having a strong installed base, and being a reliable source of supply in different countries. Illumina is a leader in the market due to its sequencing footprint at European genomics centers, which are the primary drivers of high-throughput epigenome profiling. Thermo Fisher Scientific is in a strong position through the provision of an end-to-end solution of consumables and instruments for methylation and chromatin workflows in academic labs, CROs, and biopharma sites. Merck KGaA is a prominent challenger in the European market, backed up by a complete range of products, including antibodies and chromatin reagents.

Related Reports:

Europe Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com